Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C18H18N2O3.C4H4O4 |
Molecular Weight | 426.4193 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 1 / 1 |
E/Z Centers | 1 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
OC(=O)\C=C\C(O)=O.O=C1CC2=C(N1)C=CC3=C2O[C@@H](CNCC4=CC=CC=C4)CO3
InChI
InChIKey=GELJVTSEGKGLDF-QDSMGTAFSA-N
InChI=1S/C18H18N2O3.C4H4O4/c21-17-8-14-15(20-17)6-7-16-18(14)23-13(11-22-16)10-19-9-12-4-2-1-3-5-12;5-3(6)1-2-4(7)8/h1-7,13,19H,8-11H2,(H,20,21);1-2H,(H,5,6)(H,7,8)/b;2-1+/t13-;/m0./s1
Molecular Formula | C4H4O4 |
Molecular Weight | 116.0722 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 1 |
Optical Activity | NONE |
Molecular Formula | C18H18N2O3 |
Molecular Weight | 310.3471 |
Charge | 0 |
Count |
|
Stereochemistry | ABSOLUTE |
Additional Stereochemistry | No |
Defined Stereocenters | 1 / 1 |
E/Z Centers | 0 |
Optical Activity | UNSPECIFIED |
DescriptionSources: https://www.ncbi.nlm.nih.gov/pubmed/17056032Curator's Comment: description was created based on several sources, including:
http://www.businesswire.com/news/home/20081014005485/en/Neurogen-Announces-Positive-Results-Aplindore-Restless-Legs | http://adisinsight.springer.com/drugs/800016255
Sources: https://www.ncbi.nlm.nih.gov/pubmed/17056032
Curator's Comment: description was created based on several sources, including:
http://www.businesswire.com/news/home/20081014005485/en/Neurogen-Announces-Positive-Results-Aplindore-Restless-Legs | http://adisinsight.springer.com/drugs/800016255
Aplindore (DAB-452) is a small molecule that displays potent dopamine D2 receptor partial agonist activity in in vitro and in vivo assays and is predicted to have antipsychotic efficacy without motor side effects. Aplindore had been in phase II clinical trials for the treatment of Parkinson's disease and restless legs syndrome. Aplindore was generally well tolerated and there were no withdrawals due to adverse events and no serious adverse events.
CNS Activity
Originator
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL217 Sources: https://www.ncbi.nlm.nih.gov/pubmed/17056032 |
9.1 null [pKi] | ||
Target ID: CHEMBL234 Sources: https://www.ncbi.nlm.nih.gov/pubmed/17056032 |
8.54 null [pKi] | ||
Target ID: CHEMBL219 Sources: https://www.ncbi.nlm.nih.gov/pubmed/17056032 |
7.21 null [pKi] | ||
Target ID: CHEMBL273 Sources: https://www.ncbi.nlm.nih.gov/pubmed/17056032 |
7.64 null [pKi] | ||
Target ID: CHEMBL322 Sources: https://www.ncbi.nlm.nih.gov/pubmed/17056032 |
4.87 null [pKi] | ||
Target ID: CHEMBL1907610 Sources: https://www.ncbi.nlm.nih.gov/pubmed/17056032 |
6.83 null [pKi] |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Palliative | Unknown Approved UseUnknown |
|||
Primary | Unknown Approved UseUnknown |
Sample Use Guides
In Vivo Use Guide
Sources: https://clinicaltrials.gov/ct2/show/NCT00809302
1, 3, and 6 mg twice daily
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/17056032
CHO-D2S-Gαq/o cells were challenged with various doses (up to 10 uM) of aplindore, aripiprazole and quinpirole in the absence and presence of quinpirole (10 nM). Aplindore (at 10 uM, Emax= 56 ± 1%, in the absence and 58 ± 2% in the presence of quinpirole) showed less antagonist activity than aripiprazole (at 10 uM, Emax= 33 ± 6% and 50 ± 2%, respectively) on quinpirole-mediated
[Ca2+]i response.
Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 16 18:39:28 UTC 2022
by
admin
on
Fri Dec 16 18:39:28 UTC 2022
|
Record UNII |
P13TV5A758
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C66884
Created by
admin on Fri Dec 16 18:39:28 UTC 2022 , Edited by admin on Fri Dec 16 18:39:28 UTC 2022
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
189681-71-8
Created by
admin on Fri Dec 16 18:39:28 UTC 2022 , Edited by admin on Fri Dec 16 18:39:28 UTC 2022
|
PRIMARY | |||
|
P13TV5A758
Created by
admin on Fri Dec 16 18:39:28 UTC 2022 , Edited by admin on Fri Dec 16 18:39:28 UTC 2022
|
PRIMARY | |||
|
CHEMBL2110659
Created by
admin on Fri Dec 16 18:39:28 UTC 2022 , Edited by admin on Fri Dec 16 18:39:28 UTC 2022
|
PRIMARY | |||
|
MM-21
Created by
admin on Fri Dec 16 18:39:28 UTC 2022 , Edited by admin on Fri Dec 16 18:39:28 UTC 2022
|
PRIMARY | |||
|
6440763
Created by
admin on Fri Dec 16 18:39:28 UTC 2022 , Edited by admin on Fri Dec 16 18:39:28 UTC 2022
|
PRIMARY | |||
|
C76649
Created by
admin on Fri Dec 16 18:39:28 UTC 2022 , Edited by admin on Fri Dec 16 18:39:28 UTC 2022
|
PRIMARY | |||
|
DBSALT002863
Created by
admin on Fri Dec 16 18:39:28 UTC 2022 , Edited by admin on Fri Dec 16 18:39:28 UTC 2022
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
PARENT -> SALT/SOLVATE | |||
|
PARENT -> SALT/SOLVATE |
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |